计算病理学测定的淋巴细胞密度可预测乳腺癌新辅助化疗反应:ARTemis 试验二次分析
ARTemis 试验将 800 例早期乳腺癌女性随机分配接受多西他赛、氟尿嘧啶+表柔比星+环磷酰胺方案,加或不加贝伐珠单抗。本二次分析用计算病理学量化治疗前活检和治疗后手术标本的淋巴细胞密度,发现治疗前淋巴细胞密度与病理完全缓解独立相关,而淋巴细胞密度升高与病理完全缓解呈独立负相关。
要点
- 治疗前淋巴细胞密度作为连续变量与病理完全缓解相关:单因素 OR 2.92(95%CI 1.78-4.85,P<0.001)。
- 校正临床协变量后,治疗前淋巴细胞密度仍与病理完全缓解独立相关:OR 2.13(95%CI 1.24-3.67,P=0.006)。
- 治疗前后淋巴细胞密度升高与病理完全缓解呈独立负相关:校正 OR 0.1(95%CI 0.033-0.31,P<0.001)。
核心结论
- 治疗前活检中的淋巴细胞密度被验证为乳腺癌病理完全缓解的独立预测因子。
- 计算病理学正成为识别癌症患者预测性生物标志物的一种可行且客观的手段。
研究设计与样本
- ARTemis 试验为随机对照试验,于 2009 年 5 月至 2013 年 1 月随机分配 800 例早期乳腺癌女性。
- 受试者接受 3 周期多西他赛,随后 3 周期氟尿嘧啶、表柔比星和环磷酰胺,每 21 天一次,加或不加 4 周期贝伐珠单抗。
- 主要终点为病理完全缓解(乳腺和淋巴结无浸润性癌)。
- 本分析用计算病理学方法在苏木精-伊红(H&E)全切片图像中量化淋巴细胞密度:对每个检出的淋巴细胞计算到最近 50 个淋巴细胞的平均距离,并由此统计量推导密度。
- 分析对象包括治疗前活检和治疗后手术标本的瘤床。
主要发现
- 原主要终点分析的 781 例患者中,609 例(78%)纳入基线淋巴细胞密度分析,383 例(占 781 例的 49%)纳入淋巴细胞密度变化分析;患者丢失的主要原因是数字化全切片图像的可得性。
- 治疗前淋巴细胞密度作为连续变量与病理完全缓解相关:单因素分析 OR 2.92(95%CI 1.78-4.85,P<0.001)。
- 校正临床协变量后,治疗前淋巴细胞密度与病理完全缓解相关:OR 2.13(95%CI 1.24-3.67,P=0.006)。
- 治疗前至治疗后淋巴细胞密度升高与病理完全缓解呈独立负相关:校正 OR 0.1(95%CI 0.033-0.31,P<0.001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 患者丢失的主要原因是数字化全切片图像的可得性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have previously shown lymphocyte density, measured using computational pathology, is associated with pathological complete response (pCR) in breast cancer. The clinical validity of this finding in independent studies, among patients receiving different chemotherapy, is unknown. PATIENTS AND METHODS: The ARTemis trial randomly assigned 800 women with early stage breast cancer between May 2009 and January 2013 to three cycles of docetaxel, followed by three cycles of fluorouracil, epirubicin and cyclophosphamide once every 21 days with or without four cycles of bevacizumab. The primary endpoint was pCR (absence of invasive cancer in the breast and lymph nodes). We quantified lymphocyte density within haematoxylin and eosin (H&E) whole slide images using our previously described computational pathology approach: for every detected lymphocyte the average distance to the nearest 50 lymphocytes was calculated and the density derived from this statistic. We analyzed both pre-treatment biopsies and post-treatment surgical samples of the tumour bed. RESULTS: Of the 781 patients originally included in the primary endpoint analysis of the trial, 609 (78%) were included for baseline lymphocyte density analyses and a subset of 383 (49% of 781) for analyses of change in lymphocyte density. The main reason for loss of patients was the availability of digitized whole slide images. Pre-treatment lymphocyte density modelled as a continuous variable was associated with pCR on univariate analysis (odds ratio [OR], 2.92; 95% CI, 1.78-4.85; P < 0.001) and after adjustment for clinical covariates (OR, 2.13; 95% CI, 1.24-3.67; P = 0.006). Increased pre- to post-treatment lymphocyte density showed an independent inverse association with pCR (adjusted OR, 0.1; 95% CI, 0.033-0.31; P < 0.001). CONCLUSIONS: Lymphocyte density in pre-treatment biopsies was validated as an independent predictor of pCR in breast cancer. Computational pathology is emerging as a viable and objective means of identifying predictive biomarkers for cancer patients. CLINICALTRIALS.GOV: NCT01093235.
引用
- Ali HR, Dariush A, Thomas J, et al. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. Ann Oncol. 2017. PMID: 28525534. doi:10.1093/annonc/mdx266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。